Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B–5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark
Summary: Bisphosphonates are contraindicated in moderate-to-severe chronic kidney disease patients. However, they are used to prevent fragility fractures in patients with impaired kidney function, despite a lack of evidence on their effects on bone density in these patients. We demonstrated that Alendronate had a positive effect on bone in these patients.
Purpose: This study aimed to assess the association between alendronate use and bone ...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Accepted manuscript, 484.6KB)
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Ali et al.
- Copyright date:
- Rights statement:
- Copyright © 2020 The Author(s).
This is the accepted manuscript version of the article. The final version is available from Springer at https://doi.org/10.1007/s11657-020-00746-z
If you are the owner of this record, you can report an update to it here: Report update to this record